NEW YORK, April 25, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in...

Link to original article: Foralumab eases fatigue in most SPMS patients in access program (multiplesclerosisnewstoday.com)

Foralumab found to ease fatigue in SPMS patients in access program

Use of nasal spray reduced levels after...

NEW YORK, April 23, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has...

Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary Progressive MS With PIRA

Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients.

Link to original article: Nasal Foralumab Shows Attenuation of Microglial Activation,...

• 70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-up
• All...

Link to original article: Neurology Today (lww.com)

Anti-CD3 Antibody Foralumab Shows Promise in PIRA, Measured by Novel PET Ligand

By Gina Shaw

April 4, 2024

​The fully human anti-CD3 antibody foralumab attenuates microglial activation in patients with non-active secondary progressive multiple...

• - Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -
• - Data presented in a platform...

• - Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans -

NEW YORK, April 18, 2024 –...

NEW YORK, April 11, 2024 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation...

• Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)
• Nasal anti-CD3 reduced hemorrhage and edema...